what exactly does this mean? "The sector efficacy data involving delayed onset CINV in highly emetogenic chemotherapy showed results for the higher dose of APF530 that were numerically better than palonosetron and statistically non-inferior, but did not achieve the statistically significant level of superiority necessary to support a claim in this sector."
it goes on to say "If A.P. Pharma obtains product approval for all uses except the delayed onset highly emetogenic one, the Company should have a product comparable to palonosetron,"
so what they are saying is there is nothing there to support this drug for highly emetogenic, only moderate. arent they just back where they started with kytril?
Market Data 
Markets 
AI
